Literature DB >> 16869763

Chromosomal translocation engineering to recapitulate primary events of human cancer.

A Forster1, R Pannell, L Drynan, F Cano, N Chan, R Codrington, A Daser, N Lobato, M Metzler, C-H Nam, S Rodriguez, T Tanaka, T Rabbitts.   

Abstract

Mouse models of human cancers are important for understanding determinants of overt disease and for "preclinical" development of rational therapeutic strategies; for instance, based on macrodrugs. Chromosomal translocations underlie many human leukemias, sarcomas, and epithelial tumors. We have developed three technologies based on homologous recombination in mouse ES cells to mimic human chromosome translocations. The first, called the knockin method, allows creation of fusion genes like those typical of translocations of human leukemias and sarcomas. Two new conditional chromosomal translocation mimics have been developed. The first is a method for generating reciprocal chromosomal translocations de novo using Cre-loxP recombination (translocator mice). In some cases, there is incompatible gene orientation and the translocator model cannot be applied. We have developed a different model (invertor mice) for these situations. This method consists of introducing an inverted cDNA cassette into the intron of a target gene and bringing the cassette into the correct transcriptional orientation by Cre-loxP recombination. We describe experiments using the translocator model to generate MLL-mediated neoplasias and the invertor method to generate EWS-ERG-mediated cancer. These methods mimic the situation found in human chromosome translocations and provide the framework for design and study of human chromosomal translocations in mice.

Entities:  

Mesh:

Year:  2005        PMID: 16869763     DOI: 10.1101/sqb.2005.70.008

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  10 in total

Review 1.  Genetically engineered mouse models in cancer research.

Authors:  Jessica C Walrath; Jessica J Hawes; Terry Van Dyke; Karlyne M Reilly
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

2.  Modeling and correction of structural variations in patient-derived iPSCs using CRISPR/Cas9.

Authors:  Chul-Yong Park; Jin Jea Sung; Sang-Hwi Choi; Dongjin R Lee; In-Hyun Park; Dong-Wook Kim
Journal:  Nat Protoc       Date:  2016-10-06       Impact factor: 13.491

Review 3.  The role of CALM-AF10 gene fusion in acute leukemia.

Authors:  D Caudell; P D Aplan
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

Review 4.  MLL fusions: pathways to leukemia.

Authors:  Han Liu; Emily H Y Cheng; James J D Hsieh
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

5.  EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo.

Authors:  Eun Jung Sohn; Hongjie Li; Karen Reidy; Lisa F Beers; Barbara L Christensen; Sean Bong Lee
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

6.  Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.

Authors:  Sven Bilke; Raphaela Schwentner; Fan Yang; Maximilian Kauer; Gunhild Jug; Robert L Walker; Sean Davis; Yuelin J Zhu; Marbin Pineda; Paul S Meltzer; Heinrich Kovar
Journal:  Genome Res       Date:  2013-08-12       Impact factor: 9.043

7.  Efficient Recreation of t(11;22) EWSR1-FLI1+ in Human Stem Cells Using CRISPR/Cas9.

Authors:  Raul Torres-Ruiz; Marta Martinez-Lage; Maria C Martin; Aida Garcia; Clara Bueno; Julio Castaño; Juan C Ramirez; Pablo Menendez; Juan C Cigudosa; Sandra Rodriguez-Perales
Journal:  Stem Cell Reports       Date:  2017-05-09       Impact factor: 7.765

8.  Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.

Authors:  Tomoyuki Tanaka; Roger L Williams; Terence H Rabbitts
Journal:  EMBO J       Date:  2007-06-14       Impact factor: 11.598

9.  Warburg effect and translocation-induced genomic instability: two yeast models for cancer cells.

Authors:  Valentina Tosato; Nana-Maria Grüning; Michael Breitenbach; Remigiusz Arnak; Markus Ralser; Carlo V Bruschi
Journal:  Front Oncol       Date:  2013-01-18       Impact factor: 6.244

10.  Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.

Authors:  H Sewell; T Tanaka; K El Omari; E J Mancini; A Cruz; N Fernandez-Fuentes; J Chambers; T H Rabbitts
Journal:  Sci Rep       Date:  2014-01-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.